By blocking OSA-elicited monocyte recruitment via the action of losartan inhibiting the CCL2–CCR2 axis, clinical benefits including tumor stabilization and/or regression were observed in half of the dogs. This evidence concerns the gene CCL2 and obstructive sleep apnea syndrome.